translational lung cancer research

[1] Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323.

[2] effects of alprostadil on respiratory parameters and hemodynamics of newborns with persistent pulmonary hypertension

[3] december 2013 pulmonary case of the month: natural progression

[4] proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer

[5] pemetrexed plus dendritic cells as third-line therapy for metastatic esophageal squamous cell carcinoma

[6] A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.

[7] Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy.

[8] Development of pemetrexed diacid-loaded Gelatin-Cloisite 30B (MMT) nanocomposite for improved oral efficacy against cancer: Characterization, In-vitro and Ex-vivo Assessment.

[9] Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323.

[10] proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer

[11] avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células an economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer

[12] tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed

[13] pemetrexed plus dendritic cells as third-line therapy for metastatic esophageal squamous cell carcinoma